Summary
Nature Index data for 2016–2025 puts the United States first in regenerative-medicine research output, while China’s expansion could narrow the gap if it continues.
A Nature Index analysis of research output from 2016 to 2025 places the United States first in regenerative medicine, with China emerging as a strong competitor. The analysis says the gap could shrink if China’s broader expansion in the index continues, particularly in the health sciences.
What the decade-long comparison measures
The country ranking uses Nature Index Share, the publication-output measure shown in the analysis. Its accompanying figures also compare institutions and international research partnerships. Among the 50 leading institutions for regenerative medicine, the analysis identifies 10 with the highest proportion of their Nature Index journal output in the field. At the University of Cincinnati in Ohio, that proportion is just over 10%.
The collaboration figures rank country pairs by their total bilateral collaboration score over the same decade. Nature Index says both partners contributed strongly across the leading pairings, even though the United States’ individual regenerative-medicine Share was more than 10 times that of some countries appearing in them.
Reading the rankings in context
Regenerative medicine covers research aimed at repairing, replacing or regenerating cells, tissues or organs. A publication-output comparison can show where indexed research is concentrated and how countries and institutions work together. It is not a direct measure of clinical effectiveness or of how many therapies are ready for patients.
The finding about China is therefore a conditional projection, not a forecast with a stated timetable: the gap may narrow if the expansion described in the index continues. The analysis does not provide a specific estimate for when, or by how much, that might happen.